3SBio Inc. (HKG:1530)

Market Cap	77.26B
Revenue (ttm)	9.69B
Net Income (ttm)	2.22B
Shares Out	2.39B
EPS (ttm)	0.90
PE Ratio	35.71
Forward PE	29.93
Dividend	0.25 (0.82%)
Ex-Dividend Date	Jul 21, 2025

Volume	42,445,094
Average Volume	51,715,646
Open	31.30
Previous Close	32.30
Day's Range	31.30 - 32.70
52-Week Range	5.47 - 34.20
Beta	0.74
RSI	62.50
Earnings Date	Aug 22, 2025

About Kronos Bio

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC ex...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 5,577
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1530

Financial Performance

In 2024, 3SBio's revenue was 9.11 billion, an increase of 16.53% compared to the previous year's 7.82 billion. Earnings were 2.09 billion, an increase of 34.93%.